Loading
A phase 1/2 trial of Injection of humanized nerve growth factor (NGF) antibody in advanced solid tumours, run by Shenyang Sunshine Pharmaceutical Co., LTD., now recruiting.
Phase I Study of sss40 Injection for Moderate-to-Severe Bone Metastatic Cancer Pain is a phase 1/2 interventional study registered as NCT07008703 by Shenyang Sunshine Pharmaceutical Co., LTD., with 132 participants planned, started 2024-03-27 and due to reach its primary completion in 2025-12. Interventions recorded: Injection of humanized nerve growth factor (NGF) antibody.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares 3SBio, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares 3SBio, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares 3SBio and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/